Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

BLOOD

AMER SOC HEMATOLOGY

1. Forma Therapeutics
2. Seattle Genetics
3. Research Celgene
4. Astellas
5. Actinium Pharmaceuticals, Inc.
6. Daiichi-Sankyo
7. Genentech/Roche
8. Juno Therapeutics